News
Merck and Pfizer's Bavencio approved for renal cell carcinom...
Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta (axitinib) for the first-line treatment of
